Pricing

Pieris Pharmaceuticals Inc (PIRS)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Stephen S. Yoder
Employees:
140
225 FRANKLIN STREET, 26TH FLOOR, BOSTON, MA, 02110
857-246-8998
    Formally known as:
  • MARIKA, INC COMMON STOCK
  • PIERIS PHARMACEUTICALS INC COM
  • PIERIS PHARMACEUTICALS INC COM
Pieris Pharmaceuticals, Inc. develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases. The company also develops a 4-1BB/ HER2 bispecific program addressing undisclosed targets for immuno-oncology diseases.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available